<?xml version="1.0" encoding="UTF-8"?>
<p>Geranyl acetate (100 and 200 mg/kg, i.p.) and geraniol (12.5–50 mg/kg, i.p. and 50–200 mg/kg, p.o.) were previously reported to possess significant antinociceptive activity in the writhing and glutamate tests in mice exploring antioxidant activity [
 <xref rid="B29-molecules-25-00675" ref-type="bibr">29</xref>], as well as the inhibition of Na+ voltage-sensitive sodium channels [
 <xref rid="B30-molecules-25-00675" ref-type="bibr">30</xref>], suggesting involvement in glutamatergic neurotransmission. No neurological alteration was produced by geranyl acetate, since motor performance was not modified in the rotarod test after at dosage of 200 mg/kg, i.p. [
 <xref rid="B29-molecules-25-00675" ref-type="bibr">29</xref>]. In addition, geraniol produced antiallodynic and anti-hyperalgesic effects in neuropathic pain in rats, reducing inducible nitric oxide synthase and 
 <italic>N</italic>-methyl-
 <sc>d</sc>-aspartate receptor 1 expression, as well as protein levels of TNF-α in the injured region [
 <xref rid="B31-molecules-25-00675" ref-type="bibr">31</xref>]. 
</p>
